Preventing Toxic Effects Of Protein Aggregation In Parkinson’s Disease
This article was originally published in Start Up
Executive Summary
Researchers have shown that a new class of small molecule can inhibit assembly of the protein alpha-synuclein into toxic clumps, a hallmark of Parkinson’s disease. Their work supports other ongoing investigations suggesting that the compound may be useful as a neuroprotective agent for treating a range of diseases characterized by the clumping of amyloid proteins, including Alzheimer’s disease, various types of amyloidosis, and prion disease.
You may also be interested in...
Observational Studies Reveal Commonalities Across Neurodegenerative Disorders Like Parkinson’s And Alzheimer’s
It’s all about biomarkers, biomarkers, biomarkers as huge cohort studies amass data in the hunt for clues that can aid in drug development, and the rising tide may lift more than one boat as commonalities among diseases like Alzheimer’s and Parkinson’s are discovered.
Observational Studies Reveal Commonalities Across Neurodegenerative Disorders Like Parkinson’s And Alzheimer’s
It’s all about biomarkers, biomarkers, biomarkers as huge cohort studies amass data in the hunt for clues that can aid in drug development, and the rising tide may lift more than one boat as commonalities among diseases like Alzheimer’s and Parkinson’s are discovered.
Clues From Gaucher's Disease Firm Up New Treatment Strategy For Neurodegeneration
Research linking the cause of the rare genetic disorder Gaucher's disease to mechanisms at work in Parkinsonism and other neurodegenerative conditions could become the underpinning for a broad strategy to treat neurodegeneration. It's part of a growing trend looking at molecular activities in the lysosome, a cellular compartment, for drug targets.